Trial
NCT02614508
Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Emory University
Collaborators
Novartis
Condition
Recurrent Chronic Lymphocytic Leukemia
Intervention
Buparlisib
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-09-03